1. Speaker’s name: Andrés Iñiguez  I have no potential conflicts of interest to report Potential conflicts of interest

2. Dr. Andrés Iñiguez 1 Farzin FATH-ORDOUBADHI 2, Isabel Calvo Cebollero 3, Albrecht Elsässer 4, Iskandar Atmowihardjo 5, Jorge Gaspar 6, Maciej Lesiak 7, OPPENLÄNDER Kai 8, NGUYEN Quang Ngoc 9, Ariel Roguin 10, Nicos Spyrou 11 1Hospital of Vigo, Vigo, Spain, 2Manchester Royal Infirmary, Manchester, United Kingdom, 3Miguel Servet University Hospital, Zaragoza, 4 Klinikum Oldenburg, Germany, 5Vivantes Netzwerk für Gesundheit gmbH - Am Urban, Berlin, Germany, 6Universidad Nacional Autonoma de México, 7University of Medical Sciences, Poznan, Poland, 8St. Elisabeth Klinik, Saarlouis, Germany, 9Vietnam Heart Institute, Hanoi, Viet Nam, 10Rambam Medical Centre, 11Royal Berkshire, Reading, United Kingdom Drug-eluting stent with biodegradable polymer in patients with STEMI outcomes: data from e-NOBORI and NOBORI 2 trials Drug-eluting stent with biodegradable polymer in patients with STEMI short and long term outcomes: data from e-NOBORI and NOBORI 2 trials

3. With the introduction of drug eluting stents (DES) in the last decade, treatment of patients with STEMI with these devices has emerged as a rational PCI alternative. In spite of the unquestionable benefits of DES in terms of reduction of restenosis and TVR, specific concerns have arisen with regard to their short- and long-term safety. We aim to assess short- and long-term outcomes in STEMI patients treated with Nobori, DES with biodegradable polymer. BACKGROUND NOBORI 2 / eNOBORI Registries - STEMI

4. Nobori DES Components BMS Platform Excellent Flexibility and Scaffolding Wide cell opening with optimal Side Branch Access Innovative delivery system with hydrophilic M-coating PLA Biodegradable Polymer Abluminal coating Controlled biodegradability Precise drug release kinetics Simultaneous release of drug and polymer degradation Biolimus A9™ Anti-proliferative, anti- inflammatory properties Highly lipophilic with optimal local tissue uptake NOBORI 2 / eNOBORI Registries - CTO

5. Methods Primary Endpoint: Freedom from Target Lesion Failure (TLF) defined as a composite of cardiac death, target vessel related myocardial infarction (MI) and clinically driven target lesion revascularization (TLR) at 1 year All major cardiac adverse events adjudicated by an independent CEC Clinical Follow-up NOBORI2 + eNOBORI N=1113 NOBORI2 + eNOBORI N=1113 NOBORI2 N=248 Short Term Follow-upLong Term Follow-up 1month 3years 1year Two large, prospective, single arm, multicenter Registries NOBORI 2 (N=3067) STEMI (N=248) + eNOBORI (N=9549) STEMI (N=865) NOBORI 2 / eNOBORI Registries - STEMI

6. STEMI NOBORI2 ) (N=248) STEMI eNOBORI (N=865) Age61±1260±13 Female21.820.8 DM26.923.6 Hypertension49.653.6 Current Smoker46.445.9 Previous MI37.611.4 Previous PCI11.810.3 Previous CABG0.40.7 Peripheral Vascular disease3.85.3 Renal Failure1.34.9 Baseline Characteristics NOBORI 2 / eNOBORI Registries - STEMI

7. Procedural Characteristics STEMI NOBORI2 ) (N=248) STEMI eNOBORI (N=865) Multivessel treatment, %25.019.2 N of Lesions treated1.48±0.802.10±1.56 Direct stenting28.941.8 Post-dilatation34.928.2 NOBORI 2 / eNOBORI Registries - STEMI

8. STEMI - TIMES NOBORI 2 / eNOBORI Registries - STEMI * Data only available for eNOBORI Registryc Pain to balloon

9. STEMI Location NOBORI 2 / eNOBORI Registries - STEMI * Data only available for eNOBORI Registry

10. Killip Class NOBORI 2 / eNOBORI Registries - STEMI * Data only available for eNOBORI Registry

11. STEMI Treatment * Data only available for eNOBORI Registry

12. Lesion Characteristics NOBORI 2 / eNOBORI Registries - STEMI → Data correspond to all lesions not only culprit lesions * eNOBORI counts only with true bifurcations *

13. Clinical Outcomes NOBORI 2 / eNOBORI Registries - STEMI eNOBORI + NOBORI 2 N=1113 Pts NOBORI 2 N=248 Pts

14. Stent Thrombosis (ARC) NOBORI 2 / eNOBORI Registries - STEMI + Definite and Probable Stent Thrombosis (N=1113) (N=248)

15. Use of Nobori, DES with biodegradable polymer, in the treatment of patients with STEMI was associated with favourable short and long safety and efficacy Absence of Stent thrombosis between 2 months and 3 years in this relatively large cohort of STEMI patients is particularly reassuring The design hypothesis that biodegradable polymer and abluminal coating will play an important role in the long term safety of Nobori DES is gradually being confirmed Conclusions NOBORI 2 / eNOBORI Registries - STEMI